Edwards Lifesciences Corp (NYSE:EW) price target raised to $118.00 by Citigroup

ME Staff
-
0

Analyst Ratings For Edwards Lifesciences Corp (NYSE:EW)

Today, Citigroup raised its price target on Edwards Lifesciences Corp (NYSE:EW) to $118.00 per share.

There are 15 Buy Ratings, 4 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Edwards Lifesciences Corp (NYSE:EW) is Buy with a consensus target price of $152.3158 per share, a potential 8.06% upside.

Some recent analyst ratings include

  • 7/27/2018-Guggenheim Reiterated Rating of Buy.
  • 7/27/2018-Jefferies Financial Group Reiterated Rating of Buy.
  • 7/27/2018-Northland Securities Reiterated Rating of Hold.

Recent Insider Trading Activity For Edwards Lifesciences Corp (NYSE:EW)
Edwards Lifesciences Corp (NYSE:EW) has insider ownership of 1.84% and institutional ownership of 81.06%.

  • On 7/16/2018 Larry L Wood, VP, sold 6,300 with an average share price of $148.02 per share and the total transaction amounting to $932,526.00.
  • On 7/11/2018 Donald E. Bobo, Jr., VP, sold 5,500 with an average share price of $145.57 per share and the total transaction amounting to $800,635.00.
  • On 7/5/2018 Huimin Wang, VP, sold 3,800 with an average share price of $146.60 per share and the total transaction amounting to $557,080.00.
  • On 7/3/2018 Scott B Ullem, CFO, sold 25,000 with an average share price of $145.67 per share and the total transaction amounting to $3,641,750.00.
  • On 6/15/2018 Larry L Wood, VP, sold 6,300 with an average share price of $151.86 per share and the total transaction amounting to $956,718.00.
  • On 6/13/2018 Donald E Bobo Jr, VP, sold 5,500 with an average share price of $150.00 per share and the total transaction amounting to $825,000.00.
  • On 6/6/2018 Scott B Ullem, CFO, sold 25,000 with an average share price of $141.07 per share and the total transaction amounting to $3,526,750.00.

About Edwards Lifesciences Corp (NYSE:EW)
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient's physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

Recent Trading Activity for Edwards Lifesciences Corp (NYSE:EW)
Shares of Edwards Lifesciences Corp closed the previous trading session at 141,68 −0,50 0,35 % with 382565 shares trading hands.